Contraindicated in:
Use Cautiously in:
Derm: psoriasis, skin reactions (rarely severe).
Hemat: hematologic reactions.
MS: arthralgia.
Misc: infection (including reactivation TB, hepatitis B virus [HBV] reactivation, and other opportunistic infections due to bacterial, invasive fungal, viral, mycobacterial, and parasitic pathogens), HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, SERUM SICKNESS, AND URTICARIA), lupus-like syndrome, MALIGNANCY (INCLUDING LYMPHOMA, HEPATOSPLENIC T-CELL LYMPHOMA [HSTCL], LEUKEMIA, AND SKIN CANCER).
Drug-Drug:
Crohn's Disease
Rheumatoid Arthritis or Psoriatic Arthritis
Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Plaque Psoriasis
Therapeutic Classification: gastrointestinal anti-inflammatories, antirheumatics
Pharmacologic Classification: tumor necrosis factor blockers, dmards, monoclonal antibodies
Absorption: 80% absorbed following SUBQ administration.
Distribution: Minimally distributed to tissues.
Metabolism/Excretion: Unknown.
Half-life: 14 days.
NDC Code*